Follow-on grant for Signum's skin disease programme
This article was originally published in Scrip
Executive Summary
Signum Biosciences has been awarded a $1.6 million Small Business Innovation Research (SBIR) phase II grant by the US National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (signal transduction modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.